![](https://scdn.x-mol.com/css/images/icon-new-link.png)
样式: 排序: IF: - GO 导出 标记为已读
-
Immune-checkpoint blockade in surgical management of gastric or gastro-oesophageal junction adenocarcinoma Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-06-18 Maeve A Lowery
-
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-06-18 Prof Yoon-Koo Kang MD, Masanori Terashima MD, Young-Woo Kim MD, Prof Narikazu Boku MD, Prof Hyun Cheol Chung MD, Prof Jen-Shi Chen MD, Jiafu Ji MD, Ta-Sen Yeh MD, Prof Li-Tzong Chen MD, Prof Min-Hee Ryu MD, Jong Gwang Kim MD, Takeshi Omori MD, Prof Sun Young Rha MD, Tae Yong Kim MD, Keun Won Ryu MD, Prof Shinichi Sakuramoto MD, Yasunori Nishida MD, Norimasa Fukushima MD, Takanobu Yamada MD, Li-Yuan
In Asia, adjuvant chemotherapy after gastrectomy with D2 or more extensive lymph-node dissection is standard treatment for people with pathological stage III gastric or gastro-oesophageal junction (GEJ) cancer. We aimed to assess the efficacy and safety of adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy administered in this setting. ATTRACTION-5 was a randomised, multicentre,
-
Broadening clinical indications of tenofovir alafenamide in chronic hepatitis B Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-06-17 Lung-Yi Mak
-
Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-06-17 Prof Harry L A Janssen MD, Prof Young-Suk Lim MD, Prof Pietro Lampertico MD, Prof Jeong Heo MD, Chi-Yi Chen MD, Claire Fournier MD, Tak Yin Owen Tsang MD, Ho Bae MD, Chien-Hung Chen MD, Prof Carla S Coffin MD, Sang Hoon Ahn MD, Huy Trinh MD, John F Flaherty PharmD, Frida Abramov DMSc, Yang Zhao PhD, Yang Liu PhD, Audrey Lau MD, Polina German PharmD, Prof Wan-Long Chuang MD, Kosh Agarwal MD, Prof Edward
Phase 3 studies in patients with chronic hepatitis B have shown tenofovir alafenamide to have non-inferior efficacy to tenofovir disoproxil fumarate, with improved renal and bone safety. We conducted this study to evaluate the safety and efficacy of switching to tenofovir alafenamide in participants with chronic hepatitis B and renal or hepatic impairment. This open-label, multicentre, phase 2 study
-
No accident: the UK infected blood scandal Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-06-13 The Lancet Gastroenterology & Hepatology
-
Nanoliposomal irinotecan in advanced biliary tract cancers Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-06-10 David Malka, Raphaël Colle
-
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-06-10 Prof Arndt Vogel MD PhD, Anna Saborowski MD, Patrick Wenzel MD, Prof Henning Wege MD PhD, Prof Gunnar Folprecht MD, Albrecht Kretzschmar MD, Philipp Schütt MD, Lutz Jacobasch MD, Nicolas Ziegenhagen MD, Prof Stefan Boeck MD, Danmei Zhang MD, Prof Stephan Kanzler MD, Sebastian Belle MD, Johannes Mohm MD, Eray Gökkurt MD, Christian Lerchenmüller MD, Prof Ullrich Graeven MD, Daniel Pink MD, Prof Thorsten
There is an unmet need for effective therapies in pretreated advanced biliary tract cancer. We aimed to evaluate the efficacy of nanoliposomal irinotecan and fluorouracil plus leucovorin compared with fluorouracil plus leucovorin as second-line treatment for biliary tract cancer. NALIRICC was a multicentre, open-label, randomised, phase 2 trial done in 17 German centres for patients aged 18 years or
-
Considerations for treating autistic individuals in gastroenterology clinics Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-05-29 Timothy Buie, Kara Margolis
-
Immunotherapy in biliary tract cancer: are we finally on the right path? Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-05-29 Angela Dalia Ricci, Alessandro Rizzo, Claudio Lotesoriere
-
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-05-29 Prof Do-Youn Oh MD, Prof Aiwu Ruth He MD, Mohamed Bouattour MD, Takuji Okusaka MD, Prof Shukui Qin MD, Prof Li-Tzong Chen MD, Prof Masayuki Kitano MD, Choong-kun Lee MD, Prof Jin Won Kim MD, Prof Ming-Huang Chen MD, Prof Thatthan Suksombooncharoen MD, Masafumi Ikeda MD, Prof Myung Ah Lee MD, Prof Jen-Shi Chen MD, Prof Piotr Potemski MD, Howard A Burris III MD, Prof Vikas Ostwal MD, Suebpong Tanasanvimon
In the preplanned interim analysis of the TOPAZ-1 study, durvalumab plus gemcitabine–cisplatin significantly improved overall survival versus placebo plus gemcitabine–cisplatin in participants with advanced biliary tract cancer. We aimed to report updated overall survival and safety data from TOPAZ-1 with additional follow-up and data maturity beyond the interim analysis. TOPAZ-1 was a phase 3, randomised
-
Negative screening colonoscopy and long-term colorectal cancer risk—is it time to extend the screening interval? Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-05-16 J E G IJspeert, M E van Leerdam
-
Duration of risk reduction in colorectal cancer incidence and mortality after a complete colonoscopy in Ontario, Canada: a population-based cohort study Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-05-16 Arlinda Ruco PhD, Prof Rahim Moineddin PhD, Prof Rinku Sutradhar PhD, Jill Tinmouth MD PhD, Qing Li MMath, Prof Linda Rabeneck MD MPH, M Elisabetta Del Giudice MD MSc, Catherine Dubé MD MSc, Prof Nancy N Baxter MD PhD
Colorectal cancer guidelines recommend screening colonoscopy every 10 years after a negative procedure. If risk reduction extends past 10 years, the recommended interval could be extended, reducing the burden on the individual and health-care system. We aimed to estimate the duration that patients remain at reduced risk of colorectal cancer incidence and mortality after a complete colonoscopy. We did
-
Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-05-14 Prof Marietta Iacucci MD PhD, Giovanni Santacroce MD, Irene Zammarchi MD, Yasuharu Maeda MD PhD, Rocío Del Amor BE PhD, Pablo Meseguer BE, Bisi Bode Kolawole BE, Ujwala Chaudhari BE, Prof Antonio Di Sabatino MD, Prof Silvio Danese MD PhD, Prof Yuichi Mori MD PhD, Prof Enrico Grisan BE PhD, Prof Valery Naranjo BE PhD, Prof Subrata Ghosh MD PhD
Integrating artificial intelligence into inflammatory bowel disease (IBD) has the potential to revolutionise clinical practice and research. Artificial intelligence harnesses advanced algorithms to deliver accurate assessments of IBD endoscopy and histology, offering precise evaluations of disease activity, standardised scoring, and outcome prediction. Furthermore, artificial intelligence offers the
-
Infections in cirrhosis Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-05-13 Salvatore Piano MD, Chalermrat Bunchorntavakul MD, Sebastian Marciano MD, K Rajender Reddy MD
Cirrhosis is an immune dysfunction state, and as such, patients with cirrhosis are susceptible to bacterial, fungal, and viral infections. Because of infection, these patients have a propensity to develop multiorgan failure, which is associated with high mortality. Bacterial infections are the most prevalent type of infection in patients with cirrhosis, with the prevalence of bacterial infections in
-
Rethinking colorectal cancer prognosis: beyond microsatellite status Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-05-09 Elisabetta Fenocchio
-
Clinical significance of combined tumour-infiltrating lymphocytes and microsatellite instability status in colorectal cancer: a systematic review and network meta-analysis Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-05-09 Durgesh Wankhede MS, Tanwei Yuan MSc, Prof Matthias Kloor MD, Prof Niels Halama MD, Prof Hermann Brenner MD, Prof Michael Hoffmeister PhD
Microsatellite instability (MSI) status and tumour-infiltrating lymphocytes (TIL) are established prognostic factors in colorectal cancer. Previous studies evaluating the combination of TIL and MSI status identified distinct colorectal cancer subtypes with unique prognostic associations. However, these studies were often limited by sample size, particularly for MSI-high (MSI-H) tumours, and there is
-
Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-05-06 Alexander G Miethke MD, Prof Adib Moukarzel MD, Prof Gilda Porta MD, Joshue Covarrubias Esquer MD, Piotr Czubkowski PhD, Prof Felipe Ordonez MD, Antonella Mosca MD, Amal A Aqul MD, Prof Robert H Squires MD, Prof Etienne Sokal MD, Daniel D'Agostino MD, Prof Ulrich Baumann MD, Lorenzo D'Antiga MD, Nagraj Kasi MD, Nolwenn Laborde MD, Prof Cigdem Arikan MD, Chuan-Hao Lin MD, Prof Susan Gilmour MD, Prof
Progressive familial intrahepatic cholestasis (PFIC) is a group of autosomal recessive disorders, the most prevalent being BSEP deficiency, resulting in disrupted bile formation, cholestasis, and pruritus. Building on a previous phase 2 study, we aimed to evaluate the efficacy and safety of maralixibat—an ileal bile acid transporter inhibitor—in participants with all types of PFIC. MARCH-PFIC was a
-
Targeting the EGFR signalling pathway in metastatic colorectal cancer Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-04-30 Stefania Napolitano MD PhD, Giulia Martini MD PhD, Davide Ciardiello MD PhD, Sara Del Tufo MD, Erika Martinelli MD PhD, Teresa Troiani MD PhD, Prof Fortunato Ciardiello MD PhD
Epidermal growth factor receptor (EGFR) and its activated downstream signalling pathways play a crucial role in colorectal cancer development and progression. After four decades of preclinical, translational, and clinical research, it has been shown that blocking the EGFR signalling pathway at different molecular levels represents a fundamental therapeutic strategy for patients with metastatic colorectal
-
Scottish Parliament votes to increase minimum unit price for alcohol Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-04-30 Udani Samarasekera
-
Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-04-23 Nadia Ovchinsky MD, Madeleine Aumar PhD, Prof Alastair Baker MB ChB, Prof Ulrich Baumann MD, Prof Philip Bufler Dr med, Mara Cananzi MD PhD, Piotr Czubkowski MD, Prof Özlem Durmaz MD, Prof Ryan Fischer MD, Giuseppe Indolfi MD PhD, Wikrom W Karnsakul MD, Florence Lacaille MD, Prof Way S Lee MD, Prof Giuseppe Maggiore MD, Prof Philip Rosenthal MD, Mathias Ruiz MD, Prof Etienne Sokal MD PhD, Ekkehard
In patients with Alagille syndrome, cholestasis-associated clinical features can include high serum bile acids and severe pruritus that can necessitate liver transplantation. We aimed to evaluate the efficacy and safety of the ileal bile acid transporter inhibitor odevixibat versus placebo in patients with Alagille syndrome. The ASSERT study was a phase 3, double-blind, randomised, placebo-controlled
-
Urgent action needed to achieve viral hepatitis elimination Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-04-23 The Lancet Gastroenterology & Hepatology
-
Managing irritable bowel syndrome: balancing diet and pharmacotherapy Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-04-18 Uday C Ghoshal, Uzma Mustafa, Mahesh K Goenka
-
A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised controlled trial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-04-18 Sanna Nybacka PhD, Hans Törnblom MD, Axel Josefsson MD, Johann P Hreinsson MD, Lena Böhn PhD, Åsa Frändemark MD, Cecilia Weznaver MSc, Stine Störsrud PhD, Prof Magnus Simrén MD
Dietary advice and medical treatments are recommended to patients with irritable bowel syndrome (IBS). Studies have not yet compared the efficacy of dietary treatment with pharmacological treatment targeting the predominant IBS symptom. We therefore aimed to compare the effects of two restrictive dietary treatment options versus optimised medical treatment in people with IBS. This single-centre, single-blind
-
Pathophysiology and therapeutic options for cirrhotic portal hypertension Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-04-17 Sergi Guixé-Muntet PhD, Sergio Quesada-Vázquez PhD, Prof Jordi Gracia-Sancho PhD FAASLD
Portal hypertension represents the primary non-neoplastic complication of liver cirrhosis and has life-threatening consequences, such as oesophageal variceal bleeding, ascites, and hepatic encephalopathy. Portal hypertension occurs due to increased resistance of the cirrhotic liver vasculature to portal blood flow and is further aggravated by the hyperdynamic circulatory syndrome. Existing knowledge
-
PANTS extension study: how best to use anti-TNF drugs in Crohn's disease Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-04-16 Gareth C Parkes, Charlotte R H Hedin
-
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-04-16 Neil Chanchlani PhD, Simeng Lin PhD, Claire Bewshea MSc, Benjamin Hamilton MBBS, Amanda Thomas MBBS, Rebecca Smith BMBS, Christopher Roberts MBBS, Maria Bishara BMBS, Rachel Nice MSc, Prof Charlie W Lees PhD, Prof Shaji Sebastian MD, Prof Peter M Irving MD, Prof Richard K Russell PhD, Prof Timothy J McDonald PhD, James R Goodhand MBBS, Tariq Ahmad DPhil, Nicholas A Kennedy PhD, PANTS Consortium, Vinod
We sought to report the effectiveness of infliximab and adalimumab over the first 3 years of treatment and to define the factors that predict anti-TNF treatment failure and the strategies that prevent or mitigate loss of response. Personalised Anti-TNF therapy in Crohn's disease (PANTS) is a UK-wide, multicentre, prospective observational cohort study reporting the rates of effectiveness of infliximab
-
WHO 2024 hepatitis B guidelines: an opportunity to transform care Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-04-10 Philippa J Easterbrook, Niklas Luhmann, Sahar Bajis, Myat Sandi Min, Morkor Newman, Olufunmilayo Lesi, Meg C Doherty
-
-
Addressing the evolving landscape of global malnutrition Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-04-08 The Lancet Gastroenterology & Hepatology
-
-
Validating the new nomenclature of steatotic liver disease in patients with excessive alcohol intake – Authors' reply Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-04-08 Mads Israelsen, Mary E Rinella, Aleksander Krag
-
NORPACT-1: implications for future trials – Authors' reply Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-04-08 Knut Jørgen Labori, Svein Olav Bratlie, Svein Dueland, Kristoffer Lassen
-
Has the time come for a systematic top-down approach in Crohn's disease? Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-04-08 Mathurin Fumery, Anthony Buisson
-
NORPACT-1: implications for future trials Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-04-08 Rebecca A Snyder, Matthew H G Katz
-
Validating the new nomenclature of steatotic liver disease in patients with excessive alcohol intake Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-04-08 Yu Wu, Fei Fang
-
A women-focused matrix mentorship programme in gastroenterology Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-04-08 Jalpa Devi, Kathryn Hutchins, Dawn Sears, Anita Afzali, Aline Charabaty
-
Microbiota therapeutics for inflammatory bowel disease: the way forward Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-04-08 Lukas Bethlehem PhD, Maria Manuela Estevinho MD, Ari Grinspan MD, Prof Fernando Magro PhD, Jeremiah J Faith PhD, Prof Jean-Frederic Colombel MD
Microbiota therapeutics that transplant faecal material from healthy donors to people with mild-to-moderate ulcerative colitis have shown the potential to induce remission in about 30% of participants in small, phase 2 clinical trials. Despite this substantial achievement, the field needs to leverage the insights gained from these trials and progress towards phase 3 clinical trials and drug approval
-
Fine-tuning the gut ecosystem: the current landscape and outlook of artificial microbiome therapeutics Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-04-08 Serena Porcari MD, William Fusco MD, Igor Spivak MD PhD, Marcello Fiorani MD, Antonio Gasbarrini MD, Eran Elinav MD PhD, Giovanni Cammarota MD, Gianluca Ianiro MD PhD
The gut microbiome is acknowledged as a key determinant of human health, and technological progress in the past two decades has enabled the deciphering of its composition and functions and its role in human disorders. Therefore, manipulation of the gut microbiome has emerged as a promising therapeutic option for communicable and non-communicable disorders. Full exploitation of current therapeutic microbiome
-
Liver cancer surveillance in people with hepatitis B in Africa Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-04-06 Dennis A Ndububa
-
Hepatocellular carcinoma surveillance among people living with hepatitis B in Senegal (SEN-B): insights from a prospective cohort study Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-04-06 Adrià Ramírez Mena MD, Mbaye Thiam MD, Daye Ka MD, Ibrahima Niang MD, Judicaël Tine MD, Louise Fortes MD, Kiné Ndiaye MD, Ousseynou Ndiaye PhD, Maguette Fall MD, Assietou Gaye MD, Ndeye Fatou Ngom PhD, Fatou Fall MD, Prof Annalisa Berzigotti PhD, Gregory Dale Kirk PhD, Antoine Jaquet PhD, Prof Moussa Seydi MD, Gilles Wandeler MD, SEN-B investigators
Chronic hepatitis B virus (HBV) infection is the predominant cause of hepatocellular carcinoma in west Africa, yet data on the incidence of HBV-related hepatocellular carcinoma remain scarce. We aimed to describe the uptake and early outcomes of systematic ultrasound-based hepatocellular carcinoma screening in SEN-B, which is a prospective HBV cohort in Senegal. In this prospective cohort study, we
-
Ecogastroenterology: cultivating sustainable clinical excellence in an environmentally conscious landscape Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-03-27 Kassem Sharif MD, Enrique Rodriguez de Santiago MD, Paula David MD, Prof Arnon Afek MD, Prof Ian M Gralnek MD, Prof Shomron Ben-Horin MD, Prof Adi Lahat MD
Gastrointestinal practices, especially endoscopy, have a substantial environmental impact, marked by notable greenhouse gas emissions and waste generation. As the world struggles with climate change, there emerges a pressing need to re-evaluate and reform the environmental footprint within gastrointestinal medicine. The challenge lies in finding a harmonious balance between ensuring clinical effectiveness
-
US Government, states reign in insurers' prior authorisation Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-03-20 Bryant Furlow
-
Local ablation in pancreatic cancer: some answers and more questions Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-03-19 Zachary T Berman, Rebekah R White
-
MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomised phase 2 trial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-03-19 Florentine E F Timmer MD, Bart Geboers MD, Alette H Ruarus MD, Laurien G P H Vroomen MD, Evelien A C Schouten MSc, Susan van der Lei MD, Danielle J W Vos MD, Madelon Dijkstra MD, Hannah H Schulz MD, Joyce Bakker BSc, Bente A T van den Bemd MD, Petrousjka M van den Tol MD, Robbert S Puijk MD, Birgit I Lissenberg-Witte PhD, Prof Tanja D de Gruijl PhD, Jan J J de Vries MD, Frank J Lagerwaard MD, Hester
Pancreatic ductal adenocarcinoma is an aggressive disease with a dismal prognosis. Stage III locally advanced pancreatic cancer is considered unresectable and current palliative chemotherapy regimens only modestly improve survival. Guidelines suggest chemoradiation or stereotactic ablative body radiotherapy (SABR) could be beneficial in certain circumstances. Other local treatments such as irreversible
-
Should a no-drain policy after distal pancreatectomy become standard? Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-03-16 Ulla Klaiber, Oliver Strobel
-
Prophylactic abdominal drainage after distal pancreatectomy (PANDORINA): an international, multicentre, open-label, randomised controlled, non-inferiority trial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-03-16 Eduard A van Bodegraven MD, Alberto Balduzzi MD, Tess M E van Ramshorst MD, Prof Giuseppe Malleo MD, Frederique L Vissers MD, Jony van Hilst MD, Sebastiaan Festen MD, Prof Mohammad Abu Hilal MD, Prof Horacio J Asbun MD, Nynke Michiels MD, Prof Bas Groot Koerkamp MD, Prof Olivier R C Busch MD, Freek Daams MD, Prof Misha D P Luyer MD, Marco Ramera MD, Giovanni Marchegiani MD, Prof Joost M Klaase MD,
Prophylactic passive abdominal drainage is standard practice after distal pancreatectomy. This approach aims to mitigate the consequences of postoperative pancreatic fistula (POPF) but its added value, especially in patients at low risk of POPF, is currently being debated. We aimed to assess the non-inferiority of a no-drain policy in patients after distal pancreatectomy. In this international, multicentre
-
Inconsistencies in the predictive value of PD-L1 in metastatic gastroesophageal cancer Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-03-13 Raghav Sundar, Elizabeth C Smyth
-
-
You Are What You Eat: a Twin Experiment Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-03-06 H, o, l, l, i, e, , S, h, e, r, w, o, o, d, -, M, a, r, t, i, n
-
Research in Brief Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-03-06 H, o, l, l, y, , B, a, k, e, r
-
Resmetirom for NASH: balancing promise and prudence Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-03-06 T, h, e, , L, a, n, c, e, t, , G, a, s, t, r, o, e, n, t, e, r, o, l, o, g, y, , &, , H, e, p, a, t, o, l, o, g, y
-
Gluten and non-coeliac gluten sensitivity: the nocebo effect and future avenues – Authors' reply Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-03-06 Marlijne C G de Graaf, Daniel Keszthelyi, Fred J P H Brouns, Louise Dye, Daisy M A E Jonkers, on behalf of all authors
-
The DESTIN trial: to step up or not? – Authors' reply Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-03-06 Ji Young Bang, Shyam Varadarajulu
-
The DESTIN trial: to step up or not? Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-03-06 Oscar Cahyadi, Vinay Dhir, John Leeds, Enrique de-Madaria, Nadeem Tehami
-
Comprehensive screening for superficial oesophageal squamous cell carcinoma and precancerous lesions – Authors' reply Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-03-06 Xiang-Lei Yuan, Bing Hu
-
Comprehensive screening for superficial oesophageal squamous cell carcinoma and precancerous lesions Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-03-06 Daisuke Murakami, Masayuki Yamato, Takayoshi Nishino, Makoto Arai
-
The DESTIN trial: to step up or not? Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-03-06 Avinash Tiwari, Mayank Mehrotra, Ajmal Hasan, Jaya Agarwal, Gaurav Kumar Singh
-
Gluten and non-coeliac gluten sensitivity: the nocebo effect and future avenues Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-03-06 Maurizio Mennini, Federica Ferrari, Pasquale Parisi, Giovanni Di Nardo
-
Progress is impossible without change: understanding the evolving nomenclature of steatotic liver disease and its effect on hepatology practice Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-02-28 Paul N Brennan MRCP, Oliver D Tavabie MRCP, Wenhao Li PhD, Thomas Marjot MRCP, Lynsey Corless PhD, Prof Jonathan A Fallowfield PhD, Helen Jarvis MSc, Dina Mansour MBBS, Stuart McPherson PhD, Prof William Rosenberg DPhil, Karen Rockell, Prof Jeremy Tomlinson PhD, Andrew Yeoman MD, Prof Emmanuel A Tsochatzis PhD, Prof John F Dillon MD, Prof William Alazawi PhD, Kushala W M Abeysekera PhD
The American, European, and Latin American liver societies have proposed a change in the nomenclature we use to describe alcohol-related liver disease and non-alcoholic fatty liver disease. Additionally, a term encompassing both is now advocated: steatotic liver disease, which includes metabolic dysfunction associated steatotic liver disease (MASLD) and MASLD with greater alcohol consumption (MetALD)
-
Robotic pancreatoduodenectomy: preparing for the future Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-02-28 Elisa Bannone, Giovanni Marchegiani